US EditionUS court blocks mail-order access to abortion drugs, for now
The ruling restores an in-person dispensing requirement and could force patients in every state to travel for medication abortion care, advocates said.
- On Friday, May 1, 2026, the 5th U.S. Circuit Court of Appeals issued a temporary stay blocking the Food and Drug Administration's 2023 policy permitting mail-order mifepristone, reinstating nationwide in-person dispensing requirements while Louisiana's legal challenge proceeds.
- Louisiana Attorney General Liz Murrill sued the FDA, arguing the 2023 rule undermined state abortion bans and caused the state $92,000 in Medicaid costs for emergency care from out-of-state mifepristone complications.
- Circuit Judge Stuart Kyle Duncan wrote that the policy "facilitates nearly 1,000 illegal abortions in Louisiana per month," while the panel ruled federal regulations created an end-run around the state's prohibition where medication now accounts for two-thirds of U.S. abortions.
- Julia Kaye, an American Civil Liberties Union lawyer, warned the ruling will "affect patients' access to abortion and miscarriage care in every state," while Susan B. Anthony Pro-Life America celebrated it as a "huge victory" against the "mail-order abortion drug regime."
- Legal experts anticipate a likely appeal to the Supreme Court, while providers prepare contingency plans including efforts to offer alternative misoprostol-only regimens to patients who can no longer access mifepristone via telehealth.
378 Articles
378 Articles
Abortion clash heats up at a politically fraught moment
Since the overturning of Roe v. Wade four years ago, abortions in the United States have actually increased, with the rise of abortion medication sent through the mail. Now, a nationwide ruling puts the issue back before the Supreme Court – and on the campaign trail.
Abortion Rights Movement Shifts to “Plan C” as Court Restricts Mifepristone by Mail
In a major blow to abortion access, a federal appeals court decision siding with the state of Louisiana has placed major restrictions on the abortion pill mifepristone. The medication, used in roughly two-thirds of all abortions in the U.S., can no longer be sent by mail or prescribed through telemedicine. But previous abortion restrictions show that curtailing access doesn’t reduce the prevalence of abortions. Instead, they make the procedure m…
Coverage Details
Bias Distribution
- 49% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
